REGENERON PHARMACEUTICALS, INC. — Director's Dealing 2021

Jan 5, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: REGENERON PHARMACEUTICALS, INC. (REGN)
CIK: 0000872589
Period of Report: 2020-12-31

Reporting Person: YANCOPOULOS GEORGE (Director, President and Chief Scientific)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-12-31	Performance Stock Units	$	A	620270	Acquired		Common Stock (620270)	Direct

Footnotes

F1: Each performance restricted stock unit ("PSU") represents a contingent right to receive one share of Company stock. The amount reported is the maximum number of PSUs that may be earned upon achievement of certain total shareholder return ("TSR") goals derived from compound annual growth rates of 5.6% to 19.2% over a five-year performance period ending on December 31, 2025 (or in some cases at earlier times). Between 50% and 250% of the target number of 248,108 PSUs may be earned upon achievement of such TSR goals but shall only vest at the end of the five-year performance period if the reporting person's service to the Company continues through such date, except in certain limited cases (such as if service to the Company is terminated by the Company without cause or in case of a change in control ("CIC")). Earned PSUs are subject to a mandatory holding period of three years after vesting, which ends early upon the reporting person's death or disability or a CIC.